Attralus ’s Post

View organization page for Attralus , graphic

1,775 followers

Attralus has received Breakthrough Therapy Designation for our pan-amyloid diagnostic PET imaging candidate 124I-evuzamitide (AT-01) for cardiac amyloidosis from the US FDA. ✳ Read the press release – https://lnkd.in/egNHUjnT. ✳ 124I-evuzamitide (AT-01) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration for positron emission tomography (PET) imaging in patients with suspected or known cardiac amyloidosis. ✳ FDA granted BTD for 124I-evuzamitide (AT-01) based on clinical data from Attralus-sponsored and investigator-initiated studies evaluating the use of 124I-evuzamitide in patients with cardiac amyloidosis, representing experience in more than 200 trial participants. #amyloidosis #rarediseases

  • No alternative text description for this image
Mark Timney

Global healthcare leader delivering value for patients and shareholders

2mo

Congratulations to the whole Attralus team. This is a wonderful step forward for patients!

Cristina Quarta, MD PhD

“Everyone you meet is fighting a battle you know nothing about. Be kind. Always.”

2mo

Congrats!!!!

Mary Polo

SAAG, Sacramento area Amyloidosis group. Sacramento area Amyloidosis support group facilitator Independent Hospital & Health Care Professional. Breast cancer HER2+ survivor.

2mo

Congratulations!

Like
Reply
Sarah Johnson

Clinical Research Professional

2mo

Congratulations!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics